Flatiron

The Medical University of South Carolina and Flatiron Health Announce Collaboration to Drive More Standardized, Efficient, and Effective Cancer Care

Retrieved on: 
Wednesday, March 13, 2024
Research, Technology, Clinical Trials, Health Technology, University, Health, Science, Education, Oncology, Artificial Intelligence, Evidence-based medicine, Associate, Patient, NCCN, Assist, MD, MHS, Medical school, Flatiron, MUSC, Division, Clinical Oncology, Hematology, Medicine, Nursing

The collaboration between Flatiron Health and MUSC will equip clinicians with advanced cancer care insights from Flatiron Assist, an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways, and clinical research at the point of care.

Key Points: 
  • The collaboration between Flatiron Health and MUSC will equip clinicians with advanced cancer care insights from Flatiron Assist, an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways, and clinical research at the point of care.
  • “Partnering with the Medical University of South Carolina’s Hollings Cancer Center, a market-leading cancer care provider, is an incredible opportunity to accelerate our shared vision for the delivery of more standardized, efficient, and effective cancer care,” said James Hamrick, MD, Vice President of Clinical Oncology at Flatiron Health.
  • Flatiron Assist users also adopt novel therapies an average of 59 days sooner than non-Flatiron Assist users ensuring higher quality care.
  • “This project will reduce variability in cancer treatment while increasing the quality of cancer care provided across the state of South Carolina.”

Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Technology, FDA, Health, Pharmaceutical, Oncology, Other Science, Research, Artificial Intelligence, Science, Clinical Trials, NSCLC, Cancer, Clonal hematopoiesis, Doctor of Philosophy, Artificial intelligence, Immunotherapy, Neoplasm, Pathology, TME, PCG, Effectiveness, AACR, Interface, Data, HER2, Lung cancer, Genentech, Flatiron, Roche, Biomarker, Tumor microenvironment, Abstract, Patient, Survival, Foundation Medicine, Plasma, DNA, Medical imaging

Foundation Medicine, Inc ., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.

Key Points: 
  • Foundation Medicine, Inc ., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.
  • ​Results suggest ​serial early ctDNA monitoring ​is a valuable complementary tool for real-time treatment response monitoring to targeted therapy.
  • These findings may enable personalized therapy approaches tailored to a patient’s risk of progression and downstream cancer treatment planning.
  • Follow Foundation Medicine on LinkedIn and X for more updates from #AACR24 and visit us in person at booth #3117.

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 14, 2024
ADPT, GNE, Growth, EHR, Flatiron, Genetics, Interest, Patient, MRD, IM, IND, Workflow, Cancer, Partnership, Video game

clonoSEQ test volume increased 49% to 15,680 tests delivered in the fourth quarter of 2023, compared to the fourth quarter 2022 and ended the year with 56,496 tests delivered, up 53% versus 2022.

Key Points: 
  • clonoSEQ test volume increased 49% to 15,680 tests delivered in the fourth quarter of 2023, compared to the fourth quarter 2022 and ended the year with 56,496 tests delivered, up 53% versus 2022.
  • Revenue was $45.8 million for the quarter ended December 31, 2023, representing a 17% decrease from the fourth quarter in the prior year.
  • Interest and other income, net was $4.6 million for the fourth quarter of 2023, compared to $2.6 million in the fourth quarter of the prior year.
  • Adaptive Biotechnologies will host a conference call to discuss its fourth quarter and full year 2023 financial results after market close on Wednesday, February 14, 2024 at 4:30 PM Eastern Time.

Caris Life Sciences and Flatiron Health Partner to Create Transformational Real-World Data Offering

Retrieved on: 
Monday, January 8, 2024
Real-World Evidence, RNA, RWD, Partnership, Drug discovery, Medicine, Research, Data, Sequence, MBA, DNA, Health, Doctor of Philosophy, Record, Cancer, Flatiron, AI, Patient, WES, Senior, Medical imaging

IRVING, Texas, Jan. 8, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, and Flatiron Health, a leading healthtech company transforming evidence generation through an engaged care network, oncology-specific expertise, and fit-for-purpose scientific methods and tools, today announced a partnership to create a multimodal data offering to support and accelerate biopharmaceutical drug development and patient care.

Key Points: 
  • "We are excited to collaborate with Flatiron Health to create a multimodal data offering in support of biopharma's efforts to bring novel personalized therapeutic interventions to market to ultimately improve the lives of cancer patients," said David Spetzler , MS, PhD, MBA, President of Caris Life Sciences.
  • "In forming this data union, we are able to maximize biological and clinical context to better understand each patient journey."
  • "We are thrilled to announce this groundbreaking partnership that brings together Caris' leading molecular science capabilities with Flatiron's unparalleled gold standard of high-quality oncology real-world data," said Stephanie Reisinger, Senior Vice President and General Manager, Real-World Evidence, Flatiron Health.
  • With Caris and Flatiron's combined strength and broad reach across oncology, we can provide this incredibly powerful data at a scale that will fuel drug discovery and therapeutic innovation," said Brian Lamon , PhD, Chief Business Officer of Caris Life Sciences.

Inductive Bio Emerges from Stealth, Unveiling an ML Platform to Accelerate Compound Optimization in Drug Discovery

Retrieved on: 
Wednesday, December 13, 2023
Meetup, Character, Lux Capital, ADMET, Therapy, QSAR, Data, Patient, Algorithm, Atlas Venture, Machine learning, Absorption, Flatiron, Drug discovery, Hand, Roche, Pain, ADME, Atlas, Metabolism, SVP, Genentech, Pharmaceutical industry, Induction, Venture, Toxicity

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Inductive Bio, a technology company developing a machine learning (ML) platform designed to dramatically accelerate the compound optimization process, emerged from stealth today with $4.3M in funding.

Key Points: 
  • NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Inductive Bio, a technology company developing a machine learning (ML) platform designed to dramatically accelerate the compound optimization process, emerged from stealth today with $4.3M in funding.
  • Their seed round was co-led by Andreessen Horowitz (a16z) Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and others.
  • Inductive Bio was co-founded by Josh Haimson and Ben Birnbaum who had previously built out the ML organization at Flatiron Health, which was acquired by Roche in 2018.
  • Denali has integrated custom ADME models from Inductive into their small molecule drug design platform to support rapid, data-driven decision making.

ALCHEMY 43, RAPIDLY EXPANDING AESTHETICS BRAND, NOW OFFERING GLP-1 INJECTIONS FOR WEIGHT MANAGEMENT

Retrieved on: 
Tuesday, November 28, 2023
PRP, Insulin, Eating, Kidney disease, Risk, C-peptide, Appetite, Newport Beach, California, Stroke, Flatiron, Injection, Weight loss, Blood pressure

NEW YORK, Nov. 28, 2023 /PRNewswire/ -- ALCHEMY 43 - a rapidly expanding aesthetics & wellness brand offering specialized, innovative, and technology-driven services - will now be offering GLP-1 injections for weight management.

Key Points: 
  • NEW YORK, Nov. 28, 2023 /PRNewswire/ -- ALCHEMY 43 - a rapidly expanding aesthetics & wellness brand offering specialized, innovative, and technology-driven services - will now be offering GLP-1 injections for weight management.
  • Alchemy 43, a leader in aesthetic microtreatments, has added specialized weight management services in a premium setting with consistent medical monitoring.
  • Each week, clients check in at any Alchemy 43 location for their injection.
  • For more information on ALCHEMY 43, visit: alchemy43.com and follow along on Instagram: @alchemy43 .

Crate & Barrel Launches Its First Virtual Store, an Immersive Re-Creation of Its New NYC Flagship, Powered by Obsess

Retrieved on: 
Thursday, November 16, 2023
Crate, Lighting, Senior, Crate & Barrel, Product design, Palace, Flatiron, Partnership, Environment, Life, Online shopping, Obsession, Rail profile

NEW YORK, Nov. 16, 2023 /PRNewswire-PRWeb/ -- Crate & Barrel announced today that it has launched its first immersive virtual store in partnership with experiential e-commerce platform Obsess. The fully shoppable virtual environment takes the form of Crate & Barrel's new flagship in New York City's Flatiron neighborhood, which opens today at 881 Broadway, and features engaging animations and interactive personalization tools that let customers visualize their own sofa and living room set and build their own bouquet using the brand's selection of vases and botanicals.

Key Points: 
  • NEW YORK, Nov. 16, 2023 /PRNewswire-PRWeb/ -- Crate & Barrel announced today that it has launched its first immersive virtual store in partnership with experiential e-commerce platform Obsess .
  • We're thrilled to partner with Crate & Barrel on this launch and give its online customers, and especially those not based in New York City, an immersive way to discover and shop for products offered in the brand's new flagship store.
  • The virtual store is among the largest fully 3D-rendered spaces that Obsess has created to date, offering more than 450 products and eight interactive room environments, including separate dining, kitchen, living room, botanical shop and Crate & Kids areas.
  • Every element and product in the environment is available for purchase, giving online customers a very sensory-rich, lifelike shopping experience."

Crate & Barrel Opens New Flagship Store in Heart of New York Home Design District

Retrieved on: 
Thursday, November 16, 2023
Crate, DIY, Senior, Crate & Barrel, Product design, Design, Heart, Environment, Life, Registry, Architecture, Fashion design, Department store, Interior design, Raths-Apotheke (Bremen), Flatiron

CHICAGO, Nov. 16, 2023 /PRNewswire/ -- Today, Crate & Barrel unveils a New York City flagship location in the Flatiron district. Entering the brand's first-ever immersive design store, customers can shop the brand's classic whole home design surrounded by personalized experiences, all while receiving the best service in the city. The store is a celebration of Crate & Barrel's long standing relationship with New York City and features a selection of artisanal home goods exclusive to this location.

Key Points: 
  • CHICAGO, Nov. 16, 2023 /PRNewswire/ -- Today, Crate & Barrel unveils a New York City flagship location in the Flatiron district.
  • Entering the brand's first-ever immersive design store, customers can shop the brand's classic whole home design surrounded by personalized experiences, all while receiving the best service in the city.
  • "This historic building embodies Crate & Barrel, blending classic and timeless design with a modern vision for a true flagship experience that feels right at home in the heart of New York City," says Sebastian Brauer, Senior Vice President of Product Design, Visual Crate & Barrel.
  • "Crate & Barrel Design Desk professionals merge our customers' vision with our latest technology to bring their vision from concept to reality."

Executive Coach Jerry Colonna urges leaders to embrace inclusion in 'REUNION: Leadership and the Longing to Belong' (HarperBusiness, Nov. 14)

Retrieved on: 
Tuesday, November 14, 2023
HarperCollins, Toxicity, Fred Wilson (financier), JPMorgan Chase, CCMP Capital, Flatiron, Workplace, Art, Management, Reboot

NEW YORK, Nov. 14, 2023 /PRNewswire-PRWeb/ -- Leaders are increasingly challenged to understand how to respond to a polarized world. They are grappling with division while embracing otherness. But to create welcoming environments where all team members feel recognized and comfortable being their whole selves at work, leaders must first face their own need for belonging.

Key Points: 
  • NEW YORK, Nov. 14, 2023 /PRNewswire-PRWeb/ -- Leaders are increasingly challenged to understand how to respond to a polarized world.
  • But to create welcoming environments where all team members feel recognized and comfortable being their whole selves at work, leaders must first face their own need for belonging.
  • "Your mission is not just to be a better person or to make a better company, but to work towards creating a better world.
  • Jerry Colonna is a leading executive coach who uses the skills he learned as a venture capitalist to help entrepreneurs.

World Healthcare Data Research Report 2023: Market to Triple by 2030 - New Entrants and Incumbents are Leveraging RWD/RWE to Generate Valuable Insights

Retrieved on: 
Monday, November 13, 2023
Real-World Evidence, Drug development, Acquisition, Real, Organization, Health policy, Real world evidence, Electronic health record, RWD, Public health surveillance, Ecosystem, Health information management, Procurement, COVID-19, Flatiron, Evidence, RWE, Research report, Pharmaceutical industry, Sales, Research

The report provides valuable insights into the current and future state of the RWD/RWE market.

Key Points: 
  • The report provides valuable insights into the current and future state of the RWD/RWE market.
  • These trends are leading to a rapidly growing market, which this report forecasts will experience an average 14.6% CAGR through 2030, roughly tripling today's addressable market from $4.6B to $13.6B USD.
  • The research is relevant to any healthcare stakeholder looking to leverage real-world data for evidence-based decision making.
  • The mass digitization of healthcare records over the past decade has led to an explosion of new, highly-valued clinical data assets.